Similar articles

• [Do fixed ICS/LABA-combinations have advantages in terms of patient-centered parameters?].

  Buhl R. Buhl R. Dtsch Med Wochenschr. 2009 Dec;134 Suppl 10:S381-5. doi: 10.1055/s-0029-1243046. Epub 2009 Nov 25. Dtsch Med Wochenschr. 2009. PMID: 19941241 Review. German. No abstract available.
• An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids.

  Salpeter SR. Salpeter SR. Expert Opin Drug Saf. 2010 May;9(3):407-19. doi: 10.1517/14740330903535852. Expert Opin Drug Saf. 2010. PMID: 20408768 Review.
• Asthma.

  Cates C, FitzGerald JM. Cates C, et al. Clin Evid. 2002 Jun;(7):1325-43. Clin Evid. 2002. Update in: Clin Evid. 2002 Dec;(8):1506-29. PMID: 12230750 Updated. Review. No abstract available.
• [Long-acting beta 2-agonists in addition to inhaled corticosteroids in children and adults with chronic asthma. A survey of two Cochrane reviews].

  Ulrik CS. Ulrik CS. Ugeskr Laeger. 2007 Mar 12;169(11):997-1001. Ugeskr Laeger. 2007. PMID: 17371632 Review. Danish. No abstract available.
• [Are there any advantages of a fixed combination in the treatment of asthma with respect to safety and tolerability?].

  Virchow C. Virchow C. Dtsch Med Wochenschr. 2009 Dec;134 Suppl 10:S376-80. doi: 10.1055/s-0029-1243045. Epub 2009 Nov 25. Dtsch Med Wochenschr. 2009. PMID: 19941240 Review. German. No abstract available.